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A Prospective Trial of Minimal Intensity Conditioning
with Fludarabine and Anti-CD52 Antibody Alone in
Dyskeratosis Congenita
Leslie E. Lehmann 1,2, David A. Williams 1,2,
Wendy B. London 1,2, Suneet Agarwal 1,2. 1 Pediatric Oncology,
Dana-Farber Cancer Institute, Boston, MA; 2Hematology/
Oncology, Boston Children’s Hospital, Boston, MA
Background: Dyskeratosis congenita (DC) is an inherited
bone marrow failure (BMF) syndrome classically present-
ing with a clinical triad of skin pigment abnormalities, nail
dystrophy, and oral leukoplakia. Progressive BMF occurs in
approximately 80% of patients by 30 years of age and is
the primary cause of death, followed by pulmonary failure
and malignancies. HCT for DC is limited by a high inci-
dence of treatment-related mortality, due to the exacer-
bation of underlying multi-organ disease by alkylating
agents and radiation in the conditioning regimen. DC is
caused by lesions in telomere biology genes, which
compromise cellular replicative capacity. Because of this
intrinsic cellular defect, we hypothesize that DC patients
will show acceptable rates of engraftment with a mini-
mally cytotoxic conditioning regimen that excludes
alkylating agents and radiation. Vuong et al. (Acta Hema-
tologica, 2010) have previously reported successful
engraftment in a single DC patient using ﬂudarabine and
antithymocyte globulin conditioning. Based on this ratio-
nale and experience, we initiated a prospective HCT trial
with immunosuppression-only conditioning, which would
be predicted to improve outcomes and reduce secondary
malignancies in DC patients.
Methods: Patients up to age 30 years old with a well-
matched bone marrow donor are conditioned with anti-
CD52 and ﬂudarabine, and receive cyclosporine A and
mycophenolate mofetil as graft versus host disease (GVHD)
prophylaxis. Primary outcome measures include neutrophil
engraftment at day +30 and survival at day +100, and
secondary outcome measures include rates of graft failure,
infections, GVHD, secondary malignancies, and acute and
long-term toxicities.
Results: 3 patients with DC underwent unrelated donor
HCT with one-year follow-up. 18 month-old identical
twins with TINF2 mutations and transfusion-dependent
BMF received HCT from a fully HLA-matched donor, and
were plateleteindependent and neutrophil engrafted by
day +28. Myeloid chimerism was consistently fully donor.
Lymphoid chimerism was <10% donor on day +100, and
increased to 88-95% donor by one year post-transplant.
The third patient was an 18 year-old female with DC due
to CTC1 mutations and transfusion-dependent BMF,
who underwent single allele (HLA B) mismatched HCT.
She was platelet-independent and neutrophil-engrafted
by day +21. Myeloid and lymphoid chimerism were
fully donor in the post-transplant period. Currently one
year post-HCT, all three patients are transfusion-inde-
pendent and off immunosuppression without signiﬁcant
toxicities.
Conclusions: Early data suggest the feasibility of an immu-
nosuppression-only conditioning regimen for allogeneic HCT
in patients with DC. Ongoing studies will determine the
general applicability of this regimen in a disease as hetero-
geneous as DC, and longer-term follow-up will reveal the
impact on late effects.239
High-Dose Chemotherapy with Busulfex and Melphalan
As Conditioning Regimen Followed By Autologous STEM
CELL Rescue for Pediatric Patients with High-Risk
Neuroblastoma
Menachem Bitan, Maram Abu-yaman, Nitzan Cohen-Newman,
Ronit Elhasid. Pediatric Hematology/Oncology & BMT, Tel-Aviv
Sourasky Medical Center, Tel-Aviv, Israel
Introduction: High-dose chemotherapywith stemcell rescue
(auto-transplant) became a well established consolidation
procedure for high-risk neuroblastoma patients. We summa-
rize our cumulative experience using busulfex andmelphalan
rather than carboplatin/etoposide/melphalan as preparative
regimen for transplanting these pediatric patients.
Patients & Methods: Six pediatric patients aged 4-10 year
old (median 5.75 year old), 3 males and 3 females underwent
auto-transplant. All received busulfex 0.95-1.1mg/kg/dose,16
doses on days -7 to -3 andmelphalan 140mg/m2, one dose on
day -1. Busulfex levels were measured and appeared to range
between 981-1222mM per minute (median: 1136mM per
minute), with no correction needed (normal level range of
850-1400mM per minute). Cell reconstitution included total
nuclear cell (TNC) dose of 5.01-23.7x108/kg (median
15.2x108/kg) cells, and CD34+ cell content of 4.15-9.58x106/
kg (median 6.26x106/kg) cells.
Results: Conditioning was well tolerated. No patient devel-
oped veno-occlusive-disease (VOD) of the liver. Trilineage
engraftment was documented in all patients and none
exhibited graft failure. Time to recovery of absolute neutro-
phil count>0.5x109/L was 9 - 11 (median 9) days. The time to
platelet recovery >or¼20 and >or¼50x109/L ranged from 11
to 12 (median 12) days, and from 12 to 32 (median 22) days,
respectively. One patient did not achieve platelets count
above 20x109/L and another one did not achieve platelets
count above 50x109/L, before their discharge. Hospitalization
period ranged between 23-29 days (median: 26 days).
Moderate to severe mucositis was the major adverse event
post transplant, causing all patients to be supported by total
parental nutrition (TPN) for 7-12 days (median: 11 days).
Three patients suffered from culture-negative febrile neu-
tropenia and received antibiotics until neutrophil engraft-
ment. Transplant-related mortality did not occur in any of
the patients.
Conclusions: Busulfex and melphalan -based preparative
protocols arewell tolerated, facilitate rapid engraftment with
minimal toxicity, and may be considered for pediatric pa-
tients with high-risk neuroblastoma in need for auto-trans-
plant. Larger cohort of patients is needed to further conﬁrm
our results.240
Prevalence and Impact of Poverty in Pediatric Allogeneic
Hematopoetic Stem Cell Transplant
Kira Bona 1,2, Leslie E. Lehmann 1, Wendy B. London 2,
Joanne Wolfe 2,3. 1 Pediatric Oncology, Dana-Farber Cancer
Institute, Boston, MA; 2Hematology/Oncology, Boston
Children’s Hospital, Boston, MA; 3 Psychosocial Oncology and
Palliative Care, Dana-Farber Cancer Institute, Boston, MA
Background: Despite emerging evidence of substantial
ﬁnancial distress in families of children with cancer, little is
known about the impact of economic hardship on pediatric
